



OPEN ACCESS

EDITED BY

Pengpeng Ye,
Chinese Center For Disease Control and
Prevention, China

REVIEWED BY

Lubia Velázquez López,
Instituto Mexicano del Seguro Social, Mexico
Yang Luo,
Capital Medical University, China
Yidan Guo,
Capital Medical University, China

*CORRESPONDENCE

Joel Choshi
✉ joel.choshi@ul.ac.za
Sidney Hanser
✉ Sidney.hanser@ul.ac.za

RECEIVED 29 April 2024

ACCEPTED 24 June 2024

PUBLISHED 11 July 2024

CITATION

Choshi J, Flepisi B, Mabhida SE, Sekgala MD, Mokoena H, Nkambule BB, Ndwandwe D, Mchiza ZJ, Nqebelele U, Kengne AP, Dlodla PV and Hanser S (2024) Prevalence of chronic kidney disease and associated risk factors among people living with HIV in a rural population of Limpopo Province, South Africa.
Front. Public Health 12:1425460.
doi: 10.3389/fpubh.2024.1425460

COPYRIGHT

© 2024 Choshi, Flepisi, Mabhida, Sekgala, Mokoena, Nkambule, Ndwandwe, Mchiza, Nqebelele, Kengne, Dlodla and Hanser. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Prevalence of chronic kidney disease and associated risk factors among people living with HIV in a rural population of Limpopo Province, South Africa

Joel Choshi^{1*}, Brian Flepisi², Sihle E. Mabhida³, Machoene D. Sekgala³, Haskly Mokoena¹, Bongani B. Nkambule⁴, Duduzile Ndwandwe⁵, Zandile J. Mchiza^{3,6}, Unati Nqebelele^{3,7,8}, André P. Kengne^{3,7}, Phiwayinkosi V. Dlodla^{5,9} and Sidney Hanser^{1*}

¹Department of Physiology and Environmental Health, University of Limpopo, Sovenga, South Africa,

²Department of Pharmacology, University of Pretoria, Pretoria, South Africa, ³Non-Communicable Diseases Research Unit, South African Medical Research Council, Tygerberg, South Africa, ⁴School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa, ⁵Cochrane South Africa, South African Medical Research Council, Tygerberg, South Africa, ⁶School of Public Health, University of the Western Cape, Bellville, South Africa, ⁷Department of Medicine, University of Cape Town, Cape Town, South Africa, ⁸Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa, ⁹Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa, South Africa

Background: Limited evidence informs on the prevalence of chronic kidney disease (CKD) in people living with HIV (PLWH) in South Africa. Thus, this study aimed to determine the prevalence of CKD and its associated risk factors among PLWH within the rural province of Limpopo, South Africa.

Methods: We conducted a cross-sectional study of 143 participants, subdivided into groups of PLWH ($n = 103$) and individuals without HIV ($n = 43$). Structured questionnaires were used to collect and capture sociodemographic information including age, sex, alcohol intake, smoking status, and educational status. Basic measurements taken included levels of cluster of differentiation 4 (CD4+) count, body mass index (BMI), blood pressure, plasma cystatin C, and fasting serum glucose levels. Plasma cystatin C-based estimated glomerular filtration rate (eGFR) was calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) estimator to determine the prevalence of CKD.

Results: The prevalence of CKD was approximately 7% in PLWH. Multivariate logistic regression analysis showed that it was only diabetes mellitus (odds ratio of 5.795, 95% confidence interval, $p=0.034$) and age (odds ratio of 1.078, 95% confidence interval, $p=0.039$) that were significantly associated with CKD in PLWH.

Conclusion: Chronic kidney disease was prevalent in PLWH, and it was further associated with cardiovascular risk factors, diabetes, and ageing. As PLWH age, the burden of CKD may be increased with the increase in cardiovascular-related comorbidities such as diabetes.

KEYWORDS

chronic kidney disease, people living with HIV, individuals without HIV, prevalence, risk factors

1 Introduction

Chronic kidney disease (CKD) is one of the highly prevalent non-infectious comorbidities that significantly contributes to mortality among people living with HIV (PLWH) (1). People living with HIV continue to experience a rise in the prevalence of CKD despite antiretroviral therapy, and this presents a significant challenge to healthcare systems in both developed and developing countries (2). The risk of developing CKD is higher in PLWH than in the general population, with the condition likely to progress to end-stage renal disease (ESRD) at a 2- to 20-fold higher risk (2, 3). The heightened risk is mainly due to HIV-induced renal injury, diminished CD4+ counts, treatment-related effects, and the presence of comorbidities such as diabetes and hypertension (4). In the ageing PLWH with CKD, there is an increasing co-existence of comorbidities, predominantly including diabetes, hypertension, and obesity (5) which contribute to CKD progression and poor health outcomes. The prevalence of CKD in PLWH tends to vary by geographical location, the type of estimating method, diagnostic criteria, and population characteristics (6).

One systematic review and meta-analysis reported overall CKD prevalence of 6.4, 4.8, and 12.3% among PLWH by modification in the diet in renal disease (MDRD), chronic kidney disease–epidemiology collaboration (CKD-EPI), and Cockcroft–Gault equations, respectively (7). Africa showed the highest CKD prevalence at 7.9% in PLWH according to the MDRD formula, and within the African continent, CKD prevalence was highest in West Africa at 14.6% and lowest in Southern Africa at 3.2% according to the MDRD formula (7). Observational studies within Sub-Saharan Africa also reported varying CKD prevalence ranging from 2.5 to 44%, where the lowest CKD prevalence and the highest CKD prevalence were found in Uganda and Cameroon (8, 9). Diabetes and hypertension are known to be the major driving forces for the development and progression of CKD in both the general population and PLWH (10). The higher prevalence of CKD in PLWH in Africa may also be attributed to the genetic susceptibility of people of African descent, who have an 18- to 50-fold higher risk of developing HIV-associated ESRD compared to Caucasians (11–13). South Africa has one of the highest prevalence rates of HIV globally (14), and studies reporting on the prevalence of CKD in PLWH in South Africa are scanty, underscoring the need for studies to determine the prevalence of CKD in this high-risk population. As the prevalence of CKD is often associated with hypertension, diabetes, age, obesity, and low CD4+ counts in PLWH (10, 15, 16), it is also essential to determine whether these risk factors are associated with the presence of CKD among PLWH in South Africa.

Abbreviations: ADA, American Diabetes Association; AOR, adjusted odds ratio; BMI, body mass index; CD4+, cluster of differentiation 4; CKD, chronic kidney disease; CKD-EPI, chronic kidney disease epidemiology collaboration; COR, crude odds ratio; EDTA, ethylenediaminetetraacetic acid; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HIV, human immunodeficiency virus; PLWH, people living with HIV; SPSS, Statistical Package for Social Sciences; TREC, Turfloop Research Ethics Committee.

2 Methods

2.1 Study design and ethical approval

This cross-sectional study was conducted in the Mankweng district of Limpopo Province, South Africa. The participants were recruited from 02 October 2019 to 02 October 2020. The study was approved by the Turfloop Research and Ethics Committee (TREC) (project number TREC/315/2019: PG), as part of the initial project approved by TREC (project number TREC/119/2016: PG). The study adhered to the principles of the Declaration of Helsinki (17), and informed consent was obtained from participants.

2.2 Study population, sampling technique, and eligibility criteria


A total of 146 participants (≥ 18 years) including men and women were enrolled in the study (Figure 1). The overall population ($n = 146$) consisted of PLWH ($n = 103$) and individuals without HIV ($n = 43$). The sample size was determined using a formula developed by Cochran (18), which considers a 5% margin error and 95% confidence level. Men and women aged ≥ 18 years who signed the informed consent form were allowed to participate. However, individuals found to be presenting with other comorbidities including renal dysfunction, hypertension, diabetes, dyslipidaemia, and co-infections based on medical records at the time of enrolment, as well as those who were pregnant or breastfeeding, were excluded.

2.3 Demographic data and medical information

Upon obtaining informed consent, structured questionnaires were used to collect data on sociodemographic and clinical characteristics as well as pre-existing medical conditions through screening of medical records. Anthropometric measurements including weight and height were measured using standardised protocols, as previously described (19). Body mass index (BMI) was calculated as weight in kilograms (kg) divided by the square of the height in metres (m). The BMI was further classified as underweight, normal, overweight, and obesity using the Centers for Disease Control and Prevention cutoffs (20). Blood pressure was measured using a digital Omron M2 monitor (OMRON Healthcare, Japan) according to the manufacturer's instructions. The Southern African Hypertension Guidelines were used to classify blood pressure (21).

2.4 Blood collection and biochemical analysis

A qualified nurse collected blood once-off from participants. Fasting venous blood was drawn from the median cubital vein and then transferred into ethylenediaminetetraacetic acid (EDTA) and BD vacutainer tubes (Becton Dickinson, NJ, United States). Whole blood samples were used to determine the CD4+ count at a



laboratory using a factory-calibrated Alere PIMA analyser (Alere Technologies GmbH, Germany) as per the manufacturer's instructions. The CD4+ count was classified into stages using the reference ranges described by Garcia and Guzman (22). The blood samples were further processed into serum and plasma samples using an Allegra X-30 benchtop centrifuge (Beckman Coulter, IN, United States) at 3,000 RMP and 18°C for 20 min. Serum glucose was analysed using Cobas Integra® 400 plus analyser (Roche Holding AG, Basel, Switzerland) according to the manufacturer's instructions. Diabetes was confirmed with the American Diabetes Association (ADA) criteria (23). Cystatin C was analysed in plasma samples using the Milliplex® map human kidney injury magnetic bead panel 6 assay on Luminex® xMAP® instrument (Merck KGaA, Darmstadt, Germany), according to the manufacturer's instructions. Plasma cystatin C concentrations were used to determine eGFR using the CKD-EPI formula to determine the presence of CKD, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (24). Chronic kidney disease was defined as an eGFR < 60 mL/min/1.73 m² (25).

2.5 Statistical analysis

Statistical analysis was conducted on the Statistical Package for the Social Sciences (SPSS) software version 29 (IBM Corporation, USA). The normality test was performed to check the distribution of the data. The included continuous variables (age and CD4+ count) showed a Gaussian distribution. Descriptive statistics were performed, and continuous data were presented as means and standard deviations, while categorical variables were presented as frequencies and

percentages. The independent-samples *t*-test was performed to compare the means across study groups for continuous variables while the chi-square test was used to compare the percentages for categorical variables. A logistic regression analysis was also performed to determine the factors associated with CKD. The significance difference and association level were assumed at *p*-value < 0.05.

3 Results

3.1 Demographics and clinical characteristics of the study population

The present study enrolled a total population of 146 black African adult participants consisting of PLWH (*n* = 43) and individuals without this condition (*n* = 103). The sociodemographic and clinical characteristics of the study population are presented in Table 1. The presented data showed that PLWH had a significantly higher mean age (41.91 ± 10.84) than individuals without HIV (37.09 ± 16.59) (*p* = 0.040). Individuals without HIV had a higher proportion of women (67.4%) than men (32.6%). Similarly, PLWH had a higher proportion of women (65%) than men (25%). The CD4+ count was 407.00 ± 240.87 in PLWH, whereas approximately 22% of these individuals were in the advanced HIV stage as indicated by CD4+ count < 200 cells/μL. A significantly higher proportion of PLWH consumed alcohol (27.2%) as compared to individuals without HIV (9.3%). Obesity, diabetes, and hypertension were not significantly different between the two study groups. The levels of smoking and educational status were also not significantly different between the two study groups.

3.2 Prevalence of chronic kidney disease in PLWH

Cystatin C-based eGFR was used to determine the prevalence of CKD in both PLWH and individuals without HIV in the present study. The prevalence of CKD was found to be 7% in PLWH, while no participant reported CKD in the individuals without HIV group (Figure 2).

3.3 Factors associated with chronic kidney disease in PLWH

The logistic regression analysis was performed to find any association between CKD and diabetes, age, hypertension, BMI ≥ 25 kg/m², alcohol use, and advanced HIV stage (CD4+ count <200). The results showed that diabetes (crude odd ratio = 5.795, confidence interval: 1.143–29.38; $p=0.034$) and age (crude odd ratio = 1.078, confidence interval: 1.004–1.158, $p=0.039$) were significantly associated with CKD in the crude analysis (Table 2). Both diabetes and age as well as hypertension, BMI ≥ 25 kg/m², alcohol use, and advanced HIV stage did not show any association with CKD after adjusting for sex, tobacco use, educational status, and marital status.

4 Discussion

The results for demographic characteristic features of participants showed that the mean age for PLWH was significantly higher than those without this condition. This finding currently has no statistical value as individuals without HIV were mostly young adults. Most of the PLWH in the present study were in the age group of 30–39 years, which supports the studies by Boshomane et al. (26) and Johnson and Dorrington (27) which showed that HIV is mostly prevalent among those aged ≥ 25 years, 30–34 years, or ≥ 35 years in the Limpopo Province. There were more women living with HIV than men, consistent with recent findings by Johnson and Dorrington (27), which showed a disproportionately higher prevalence of HIV in women than in men in Limpopo Province. This may be attributed to the heightened risk in women due to socioeconomic, behavioural, and biological factors (28). For instance, women are mostly likely to find themselves unemployed and in poverty, which promotes unsafe sex practises, such as engaging in transactional sex with casual partners without protection (29). Our results also showed a higher proportion of PLWH who are single, corroborating previous findings that report an increased risk of HIV among single individuals compared to married or cohabiting individuals due to their likelihood of engaging in risky behaviours such as having multiple partners and engaging in transactional sex (26, 30, 31). In terms of educational status, this study showed that most of the PLWH were at the secondary school level. On the contrary, a previous study reported a higher HIV prevalence among people with primary education or no formal education than those with secondary education in the Limpopo Province (26). Despite this, our finding reflects higher HIV transmission rates in the early adolescent stages when they were still in school, possibly due to sexual experimentation and engaging in unsafe sex practises with multiple partners.

TABLE 1 Sociodemographic and clinical characteristics of the study population.

	Individuals without HIV	PLWH	<i>p</i>
	<i>n</i> = 43	<i>n</i> = 103	
Age (years)	37.09 \pm 16.59	41.91 \pm 10.84	0.040
Age group, <i>n</i> (%)			
18–29	18 (41.9)	14 (13.6)	
30–39	13 (30.2)	34 (33.0)	
40–49	3 (7.0)	31 (30.1)	<0.001
≥ 50	9 (20.9)	24 (23.3)	
Sex, <i>n</i> (%)			
Female	29 (67.4)	67 (65.0)	0.781
Male	14 (32.6)	36 (35.0)	
CD4+ count (cells/ μ L)	–	407.00 \pm 240.87	–
CD4+ category, <i>n</i> (%)			
≥ 200	–	72 (78.3)	–
<200	–	20 (21.7)	
Marital status, <i>n</i> (%)			
Single	27 (62.8)	53 (51.5)	0.359
Married	10 (23.3)	26 (25.2)	
Cohabiting	6 (14.0)	24 (23.3)	
Education status, <i>n</i> (%)			
No formal education	1 (2.3)	7 (6.8)	0.590
Primary	6 (14.0)	14 (13.6)	
Secondary	30 (69.8)	73 (70.9)	
Tertiary	6 (14.0)	9 (8.7)	
Alcohol consumption, <i>n</i> (%)	4 (9.3)	28 (27.2)	0.017
Smoking, <i>n</i> (%)	7 (16.3)	25 (24.3)	0.287
BMI category (kg/m ²), <i>n</i> (%)			
Underweight	0	8 (7.8)	0.052
Normal	17 (39.5)	40 (38.8)	
Overweight	9 (20.9)	32 (31.1)	
Obese	17 (39.5)	23 (22.3)	
Diabetes, <i>n</i> (%)	5 (11.6)	14 (13.6)	0.748
Hypertension, <i>n</i> (%)	7 (16.3)	25 (24.3)	0.287

HIV, human immunodeficiency virus; CD4+, cluster of differentiation 4. Continuous data are expressed as mean \pm standard deviation and categorical data as frequency and percentage. The bold text indicates *p*-values <0.05.

We found a higher prevalence of CKD in PLWH than in HIV-uninfected individuals (no CKD case), which is comparable with the overall CKD prevalence of 7.9% in PLWH in Africa (7). Our finding is also comparable with the findings of Gunter et al. (32) from Belgium and Goulet et al. (33) from the United States who reported CKD prevalence rates of 7.8 and 7% in HIV-infected individuals using creatinine-based measures. In the logistic analysis, diabetes and age were associated with CKD in our PLWH, suggesting that as the HIV population ages, comorbidities such as diabetes develop and become prevalent, predisposing individuals to the risk of developing CKD. A

similar study by Debeb et al. (34) in Ethiopia also showed that older age and diabetes were significantly associated with CKD in PLWH. Our CKD prevalence in PLWH was lower than the prevalence reported by Calza et al. (35) from Italy (21.3%), which was associated with multiple risk factors including older age, hypertension, diabetes, male gender, low nadir CD4+ count, hypertriglyceridemia, and use of tenofovir. In addition, Calza et al. (35) used a sensitive CKD diagnostic criterion incorporating urinalysis, which could explain this disparity. The majority of our PLWH were not in the advanced HIV stage and were under the 50-year age group, which could also explain the disparity with Calza et al. (35) study. On the other hand, we found a much higher CKD prevalence than Nyende et al. (8) from Uganda (2.5%), who attributed the low prevalence to the small sample size and not receiving critically ill outpatients.

Ageing and diabetes may explain the higher prevalence of CKD in our PLWH. Diabetes is a well-recognised traditional risk factor for CKD (10) and contributes to renal disease via hyperfiltration stress, hyper-reabsorption stress, or endothelial dysfunction (36). On the other hand, ageing is a strong unmodifiable risk factor for CKD among PLWH and as they age, comorbidities increase, and CKD becomes more prevalent (2). Ageing is also known to facilitate renal function deterioration in both the general population and PLWH,

which is related to increased levels of oxidative stress resulting in structural and functional changes in the kidney (37). The higher prevalence of CKD in our PLWH may also be explained by the genetic predisposition that HIV-infected Africans have for HIV-related renal disease. People of African descent are known to carry APOL1 kidney disease risk variants, which are strongly associated with the progression of HIV-associated nephropathy to CKD and ESRD during HIV infection (38). In addition to the traditional risk factors such as ageing and diabetes, PLWH is also susceptible to other comorbidities, especially Hepatitis C infections, which may also account for the higher prevalence of CKD in PLWH, as explained by Ranivoharisoa et al. (39). Moreover, HIV infection has a direct effect on causing renal function decline, and the detrimental effect of antiretroviral medication further contributes to an increased risk of developing CKD among the PLWH (4). Our finding suggests that PLWH may soon experience ESRD and warrants further investigation.

Other risk factors including hypertension, BMI ≥ 25 kg/m², alcohol use, and advanced HIV stage were not significantly associated with CKD in our population, which may be explained by the fact that few had CD4+ count <200 cells/ μ L and were in ≥ 50 -year age group. The risk factors correlate well with CKD among older patients (40). The study is limited by its cross-sectional nature which makes it impossible to infer causation. The disparity in the number of individuals between the study groups may have influenced the outcomes of the study. The current study observed a significant association between age and diabetes with CKD in the crude analysis, which did not persist after adjusting for some potential confounders. This may reflect that these risk factors were masked by other consequences, requiring further elaboration in future studies. Therefore, the high presence of CKD among the PLWH may reflect the interaction of risk factors, rather than their independent contributions in increasing the risk of CKD among PLWH. Furthermore, this study was conducted in a single district in the Limpopo Province, which potentially limits the generalisability of the findings. Cross-sectional studies usually do not have a control group. This study did not compare the clinical data of PLWH with CKD and non-CKD. Although the study is not without limitations, the preliminary information proves vital in understanding risk factors associated with CKD among PLWH. Importantly, the results are vital




TABLE 2 Logistic analysis of risk factors associated with chronic kidney disease in PLWH.

		COR (95%CI)	p	AOR (95%CI)	p
Diabetes	No (ref)	5.795 (1.143–29.38)	0.034	6.340 (0.901–44.597)	0.064
	Yes				
Age		1.078 (1.004–1.158)	0.039	1.109 (0.984–1.184)	0.107
Hypertension	No (ref)	1.720 (0.231–6.988)	0.784	1.604 (0.258–9.996)	0.613
	Yes				
BMI	<25 (ref)	0.635 (0.135–2.990)	0.565	1.029 (0.153–6.903)	0.977
	≥ 25				
Alcohol consumption	No (ref)	2.130 (0.445–10.185)	0.344	2.559 (0.400–16.369)	0.321
	Yes				
CD4+ count	≥ 200 (ref)	0.705 (0.078–10.185)	0.344	2.559 (0.400–16.369)	0.321
	<200				

Variables adjusted: sex, tobacco use, educational status, and marital status. COR, crude odds ratio; CD4+, cluster of differentiation 4; AOR, adjusted odd ratio; CI, confidence interval; p, significance level. The bold values indicate p-values < 0.05 .

to build on future research to understand the epidemiology of this condition in a Black African population, especially for countries in Southern Africa. Furthermore, the study encourages the potential use of cystatin C-based measures for determining the presence of kidney disease in this high-risk group of PLWH, as previously highlighted (41).

5 Conclusion

The prevalence of CKD is higher in PLWH than in individuals without HIV and is associated with ageing and diabetes. This suggests that the risk of future adverse renal outcomes may be increased in this HIV population. Future longitudinal studies incorporating larger sample sizes are needed to confirm these findings.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by Turfloop Research Ethics Committee, University of Limpopo. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

JC: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. BF: Supervision, Writing – review & editing. SM: Data curation, Formal analysis, Writing – review & editing. MS: Data curation, Formal analysis, Writing – review & editing. HM: Writing – review & editing. BN: Writing – review & editing. DN: Writing – review & editing. ZM: Writing – review & editing. UN: Writing – review & editing. AK: Writing – review & editing. PD: Conceptualization, Funding acquisition, Investigation, Methodology,

Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. SH: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. PD was supported in part by the National Research Foundation (NRF) (Grant numbers: 117829 and 141929). SH was also funded by the NRF Thuthuka Programme (Grant No. 107249), Health and Welfare Sector Education and Training Authority (South Africa), and the University of Limpopo (UL). JC was partially supported by funding from the SAMRC through its division of Research Capacity Development under the Internship Scholarship Programme. SM was also partially supported by funding from the SAMRC through its division of Research Capacity Development under the Intra-Mural Postdoctoral and Doctoral Fellowship Programme from funding received from the South African Treasury. The content hereof is the sole responsibility of the authors and does not necessarily represent the official views of the SAMRC or the funders.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Naicker S, Rahmanian S, Kopp JB. HIV and chronic kidney disease. *Clin Nephrol.* (2015) 83:32–8. doi: 10.5414/CNP83S032
2. Heron JE, Bagnis CI, Gracey DM. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV. *AIDS Res Ther.* (2020) 17:11–3. doi: 10.1186/s12981-020-00266-3
3. Wyatt CM. Kidney disease and HIV infection. *Top Antivir Med.* (2017) 25:13–6.
4. Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. *Kidney Int.* (2018) 93:545–59. doi: 10.1016/j.kint.2017.11.007
5. Park J, Zuñiga JA. Chronic kidney disease in persons living with HIV: a systematic review. *J Assoc Nurses AIDS Care.* (2018) 29:655–66. doi: 10.1016/j.jana.2018.04.004
6. Pontes PS, Ruffino-Netto A, Kusumoto L, Costa CRB, Gir E, Reis RK. Factors associated to chronic kidney disease in people living with HIV/AIDS. *Rev Lat Am Enfermagem.* (2020) 28:e3331. doi: 10.1590/1518-8345.3553.3331
7. Ekrikpo UE, Kengne AP, Bello AK, Effa EE, Noubiap JJ, Salako BL, et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. *PLoS One.* (2018) 13:e0195443. doi: 10.1371/journal.pone.0195443
8. Nyende L, Kalyesubula R, Sekasanvu E, Byakika-Kibwika P. Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study. *BMC Nephrol.* (2020) 21:232. doi: 10.1186/s12882-020-01873-y
9. Halle MP, Moussa O, Francois K, Yacouba M, Hugo M, Henry L. Prevalence and associated factors of chronic kidney disease among patients infected with human immunodeficiency virus in Cameroon. *Iran J Kidney Dis.* (2018) 12:268–74.

10. Kaze AD, Ilori T, Jaar BG, Echouffo-Tcheugui JB. Burden of chronic kidney disease on the African continent: a systematic review and meta-analysis. *BMC Nephrol.* (2018) 19:125. doi: 10.1186/s12882-018-0930-5
11. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. *J Infect Dis.* (2008) 197:1548–57. doi: 10.1086/587994
12. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. US renal data system 2011 annual data report. *Am J Kidney Dis.* (2012) 59:A7. doi: 10.1053/j.ajkd.2011.11.015
13. Dummer PD, Limou S, Rosenberg AZ, Heymann J, Nelson G, Winkler CA, et al. APOL1 kidney disease risk variants: an evolving landscape. *Semin Nephrol.* (2015) 35:222–36. doi: 10.1016/j.semnephrol.2015.04.008
14. Naidoo I, Takatshana S, Sewpaul R, Jooste S, Siyanai Z, Maseko G, et al. Past and current status of adolescents living with HIV in South Africa, 2005–2017. *BMC Res Notes.* (2022) 15:132. doi: 10.1186/s13104-022-06006-2
15. Hasan M, Sutradhar I, Gupta RD, Sarker M. Prevalence of chronic kidney disease in South Asia: a systematic review. *BMC Nephrol.* (2018) 19:291–5. doi: 10.1186/s12882-018-1072-5
16. Calza L, Sachs M, Colangeli V, Borderi M, Granozzi B, Malosso P, et al. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy. *Clin Exp Nephrol.* (2019) 23:1272–9. doi: 10.1007/s10157-019-01768-9
17. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA.* (2013) 310:2191–4. doi: 10.1001/jama.2013.281053
18. Cochran WG. Methodological problems in the study of human populations. *Ann N Y Acad Sci.* (1963) 107:476–89. doi: 10.1111/j.1749-6632.1963.tb13293.x
19. Mashiane JT, Monyeki KD, Kengne AP, Rosina NM, Monyeki MS. Ellisras longitudinal study conference 2017: the relationship between dietary intake and body mass index among young rural adults in South Africa aged 18 to 30 years (ELS 18). *Cardiovasc J Afr.* (2018) 29:301–4. doi: 10.5830/CVJA-2018-033
20. Centers for Disease Control and Prevention. All about adult BMI. (2022). Available at: https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html (Accessed January 26, 2024).
21. Hypertension guideline working group Seedat YK, Rayner BL, Veriava Y. South African hypertension practice guideline 2014. *Cardiovasc J Afr.* (2014) 25:288–94. doi: 10.5830/CVJA-2014-062
22. Battistini Garcia SA, Guzman N. Acquired immune deficiency syndrome CD4+ count. Treasure Island, FL: StatPearls Publishing LLC (2024).
23. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. *Diabetes Care.* (2018) 41:S13–27. doi: 10.2337/dc18-S002
24. Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int.* (2024) 105:S117–314. doi: 10.1016/j.kint.2023.10.018
25. Estrella MM, Jaar BG, Cavanaugh KL, Fox CH, Perazella MA, Soman SS, et al. Perceptions and use of the national kidney foundation KDOQI guidelines: a survey of U.S. renal healthcare providers. *BMC Nephrol.* (2013) 14:230. doi: 10.1186/1471-2369-14-230
26. Boshomane IT, Tshabalala KD, Mokoena OP, Ntuli TS. Prevalence and risk factors associated with HIV infection among pregnant antenatal care attendees in Limpopo Province, South Africa. *Berkala Kedokteran.* (2024) 20:39–51. doi: 10.20527/jbk.v20i1.18773
27. Johnson L, Dorrington R. Modelling the impact of HIV in South Africa's provinces: 2023 updated. Centre for Infectious Disease Epidemiology and Research working paper. (2023).
28. Sia D, Onadja Y, Hajizadeh M, Heymann SJ, Brewer TF, Nandi A. What explains gender inequalities in HIV/AIDS prevalence in sub-Saharan Africa? Evidence from the demographic and health surveys. *BMC Public Health.* (2016) 16:1–18. doi: 10.1186/s12889-016-3783-5
29. Bandali S. Exchange of sex for resources: HIV risk and gender norms in Cabo Delgado. *Mozambique.* (2011) 13:575–88. doi: 10.1080/13691058.2011.561500
30. Mabaso M, Sokhela Z, Mohlabane N, Chibi B, Zuma K, Simbayi L. Determinants of HIV infection among adolescent girls and young women aged 15–24 years in South Africa: a 2012 population-based national household survey. *BMC Public Health.* (2018) 18:183. doi: 10.1186/s12889-018-5051-3
31. Anoubissi JD, Gabriel EL, Nde CK, Fokam J, Tseuko DG, Messeh A, et al. Factors associated with risk of HIV-infection among pregnant women in Cameroon: evidence from the 2016 national sentinel surveillance survey of HIV and syphilis. *PLoS One.* (2019) 14:e0208963. doi: 10.1371/journal.pone.0208963
32. Gunter J, Callens S, De Wit S, Goffard J, Moutschen M, Darcis G, et al. Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study. *Acta Clin Belg.* (2018) 73:50–3. doi: 10.1080/17843286.2017.1339965
33. Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? *Clin Infect Dis.* (2007) 45:1593–601. doi: 10.1086/523577
34. Debeb SG, Muche AA, Kifle ZD, Sema FD. Tenofovir Disoproxil fumarate-associated renal dysfunction among adult people living with HIV at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019: a comparative retrospective cohort study. *HIV AIDS.* (2021) 13:491–503. doi: 10.2147/HIV.S308339
35. Calza L, Vanino E, Magistrelli E, Salvadori C, Cascavilla A, Colangeli V, et al. Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. *Clin Exp Nephrol.* (2014) 18:104–12. doi: 10.1007/s10157-013-0817-5
36. Anders H, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. *Nat Clin Pract Nephrol.* (2018) 14:361–77. doi: 10.1038/s41581-018-0001-y
37. Glasscock RJ, Rule AD. Aging and the kidneys: anatomy, physiology and consequences for defining chronic kidney disease. *Nephron Clin Pract.* (2016) 134:25–9. doi: 10.1159/000445450
38. Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. *J Am Soc Nephrol.* (2015) 26:2882–90. doi: 10.1681/ASN.2014050469
39. Ranivoharisoa EM, Tongavelona J, Rabemiarason RN, Ramilitiana B, Randriamanantsoa LN, Randria MJD, et al. Chronic kidney disease related to human immunodeficiency virus infection and acquired immune deficiency syndrome: a single study in Madagascar. *Int J Nephrol Kidney Fail.* (2018) 4:2. doi: 10.16966/2380-5498.158
40. Pelchen-Matthews A, Ryom L, Borges AH, Edwards S, Duvivier C, Stephan C, et al. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. *AIDS.* (2018) 32:2405–16. doi: 10.1097/QAD.0000000000001967
41. Hanser S, Choshi J, Mokoena H, Mabhida SE, Mchiza ZJ, Moetlediwa MT, et al. A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy. *Front Med.* (2024) 11:1295217. doi: 10.3389/fmed.2024.1295217